Eli Lilly (LLY) Releases Positive Results From Phase 3 VIVID-2 Open-Label Extension Study

Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Buy and Hold For the Next 3 Years. On February 19, Eli Lilly and Company (NYSE:LLY) released positive results from the Phase 3 VIVID-2 open-label extension study. The study is testing Omvoh (mirikizumab-mrkz) to treat Crohn’s disease and ulcerative colitis.

​The study found durable remission in Crohn’s, as patients with moderate-to-severe Crohn’s stayed in remission after 3 years of treatment. Moreover, data from VIVID-1 (Crohn’s) and LUCENT-3 (ulcerative colitis) trials showed that the treatment requires minimal hospitalizations and surgeries. Management noted that Omvoh is the first IL-23p19 inhibitor with proven efficacy over 4 years in ulcerative colitis and 3 years in Crohn’s.

​Efficacy results at 152 weeks showed 92.4% clinical remission and 91.2% Corticosteroid-free clinical remission. Adrienne Brown, President of Immunology at Eli Lilly and Company (NYSE:LLY), noted that the trial proves that Omvoh helps patients achieve sustained control, potentially changing disease progression.

​Eli Lilly and Company (NYSE:LLY) is a pharmaceutical manufacturer. It develops treatments across therapeutic areas, including diabetes, oncology, immunology, and neuroscience.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.